Physician profile
Robert J Gardella
NPI 1770540932
$200,746.67
in general payments reported to CMS, 2019-2025
15 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $7,986 · 2021: $14K · 2022: $7,050 · 2023: $29K · 2024: $19K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Travel and Lodging: $6,619 · Food and Beverage: $5,415 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,414.00 |
| Travel and Lodging | $6,618.79 |
| Food and Beverage | $5,415.23 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $110,123.07 | 2023-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $70,418.03 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Janssen Pharmaceuticals, INC | $9,978.50 | 2019-2023 | Invega |
| Sunovion Pharmaceuticals INC. | $8,021.03 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $670.66 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $569.08 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $255.33 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $240.56 | 2023-2024 | Igalmi |
| Lundbeck LLC | $140.79 | 2019-2024 | Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $103.80 | 2019-2024 | Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $71.50 | 2024 | |
| Abbvie INC. | $61.30 | 2024 | |
| Janssen Scientific Affairs, LLC | $39.23 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.68 | 2025 | Abilify Asimtufii |
| Indivior INC. | $19.11 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gardella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.